A Randomized, Double-blind, Placebo Controlled, Single Ascending Dose and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of FP-025, a Matrix Metalloproteinase-12 (MMP-12) Inhibitor, in Healthy Male Subjects

Trial Profile

A Randomized, Double-blind, Placebo Controlled, Single Ascending Dose and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of FP-025, a Matrix Metalloproteinase-12 (MMP-12) Inhibitor, in Healthy Male Subjects

Recruiting
Phase of Trial: Phase I

Latest Information Update: 26 Jan 2017

At a glance

  • Drugs FP 025 (Primary)
  • Indications Asthma; Chronic obstructive pulmonary disease
  • Focus Adverse reactions
  • Sponsors Foresee Pharmaceuticals
  • Most Recent Events

    • 26 Jan 2017 Status changed from not yet recruiting to recruiting, according to a Foresee Pharmaceuticals media release.
    • 18 Dec 2015 Planned End Date changed from 1 Dec 2015 to 1 Dec 2017 as reported by ClinicalTrials.gov.
    • 18 Dec 2015 Planned primary completion date changed from 1 Nov 2015 to 1 Dec 2017 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top